Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Can NPC1L1 inhibitors reduce the risk of biliary tract cancer? Evidence from a mendelian randomization study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 1 Sept 2024

Dong Hao, Chen Rong, Wang Jiafeng, Chai Ningli, Linghu Enqiang

Abstract excerpt

BACKGROUND & AIMS: Oxysterols have been implicated in biliary tract cancer (BTC), and Niemann-Pick C1-like 1 (NPC1L1) has been associated with oxysterol uptake in biliary and intestinal cells. Thus, our study aims to investigate the potential causal link between genetically proxied NPC1L1 inhibitors and the risk of BTC. METHODS: In this study, we employed two genetic instruments as proxies for NPC1L1 inhibitors,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Biliary Tract Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Ezetimibe

Share to Membrane Proteins

Share to Membrane Transport Proteins

Share to Mendelian Randomization Analysis

Share to Quantitative Trait Loci

Source

Identifiers

PMID: 38342741
DOI: 10.1016/j.dld.2024.01.211

Genes

NPC1L1
BTC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Can NPC1L1 inhibitors reduce the risk of biliary tract cancer? Evidence from a mendelian randomization study.PMID 38342741Read ↗

Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer.Semantic proximity Read ↗

Mendelian randomization study of circulating lipids and biliary tract cancer among East Asians.Semantic proximity Read ↗

Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation study.Semantic proximity Read ↗

Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: a Mendelian randomization studySemantic proximity Read ↗

Lipids, lipid-modifying drug Target genes and Bladder cancer: a Mendelian randomization studySemantic proximity Read ↗

Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.Semantic proximity Read ↗

Mendelian randomization analysis of risk factors for nasopharyngeal carcinoma: Examining causal links to EBV susceptibility and dietary influences.Semantic proximity Read ↗

The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug TargetingSemantic proximity Read ↗

Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.Semantic proximity Read ↗

Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease.Semantic proximity Read ↗

Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.Semantic proximity Read ↗

Genetically proxied PCSK9 inhibition provides indication of lower prostate cancer risk: a Mendelian randomization studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.